Ono Pharmaceutical Co Ltd (OPHLF)
10.89
+0.19
(+1.79%)
USD |
OTCM |
Dec 16, 15:58
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 5.116B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -39.05% |
| Valuation | |
| PE Ratio | 6.352 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 1.540 |
| Price to Book Value | 0.9337 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.2673 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 88.80% |
Profile
| Ono Pharmaceutical Co Ltd is a drug manufacturer with a focus on drug discovery in areas of unmet medical needs. It maintains a world-wide business in specialty pharmaceuticals. The company breaks out its revenue of goods and products into eight segments. The vast majority of Ono's revenue is derived from its circulatory and respiratory drugs, followed by its metabolic drugs and vitamins. The company also reports revenue derived from royalties. The bulk of Ono's sales are generated in Japan, followed by the rest of Asia and Europe. |
| URL | http://www.ono.co.jp |
| Investor Relations URL | N/A |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Mid Cap/Value |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | Mar. 28, 2025 |
| Last Ex-Dividend Date | Sep. 27, 2024 |
Ratings
Profile
| Ono Pharmaceutical Co Ltd is a drug manufacturer with a focus on drug discovery in areas of unmet medical needs. It maintains a world-wide business in specialty pharmaceuticals. The company breaks out its revenue of goods and products into eight segments. The vast majority of Ono's revenue is derived from its circulatory and respiratory drugs, followed by its metabolic drugs and vitamins. The company also reports revenue derived from royalties. The bulk of Ono's sales are generated in Japan, followed by the rest of Asia and Europe. |
| URL | http://www.ono.co.jp |
| Investor Relations URL | N/A |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Mid Cap/Value |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | Mar. 28, 2025 |
| Last Ex-Dividend Date | Sep. 27, 2024 |